Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Boehringer Ingelheim
Biotech
GSK offers Rgenta up to $500M biobucks per target in RNA deal
The partners will work to develop new splice modulators across multiple disease areas, with Rgenta able to make up to nearly $500 million per target.
Darren Incorvaia
Dec 4, 2024 8:00am
Biophama VC, deal values and exits all rise in Q3: Pitchbook
Nov 20, 2024 6:15am
Boehringer drops obesity drug from Gubra partnership
Oct 31, 2024 1:22pm
Notable goes bankrupt, ending plans for Boehringer cancer drug
Oct 15, 2024 8:45am
Boehringer inks $607M Circle pact for preclinical cancer program
Oct 9, 2024 8:36am
Boehringer's phase 3 lung fibrosis trial hits primary endpoint
Sep 16, 2024 8:30am
